Company: IMRX
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001790340-25-000053
Chunk: 35

Company: Immuneering Corp
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 35
---
#### Narrative to 2024 Summary Compensation Table
Our executive compensation program is designed to align compensation with business objectives and the creation of stockholder value, while also enabling us to attract, motivate and retain individuals who contribute to our long-term success. For 2024, the compensation of our named executive officers primarily consisted of a base salary, an annual cash incentive bonus opportunity, equity compensation in the form of stock options and health and welfare benefits. Pursuant to their employment agreements, the named executive officers are also eligible to receive certain payments and benefits upon a termination of employment under certain circumstances.

#### 2024 Base Salaries
Our named executive officers receive a base salary to compensate them for services rendered to the Company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role and responsibilities. Annual base salaries are reviewed periodically by the compensation committee and the Board of Directors. Effective January 1, 2024, the compensation committee approved an

<div align='center'>24</div>

TABLE OF CONTENTS

increase in the base salary for Dr. Zeskind from $593,096 to $616,820, for Dr. Hall from $678,132 to $705,257, and for Mr. Bookman from $463,000 to $482,777.

In February 2025, our compensation committee approved an increase in the base salary for Dr. Zeskind from $616,820 to $641,493, for Dr. Hall from $705,257 to $733,468, and for Mr. Bookman from $482,777 to $502,089, each effective as of January 1, 2025.

#### 2024 Bonuses
We offer our named executive officers the opportunity to earn annual performance bonuses to compensate them for attaining short-term company and individual goals established by our Board of Directors. Each named executive officer has an established target annual performance bonus amount, expressed as a percentage of the named executive officer’s annual base salary. The target bonus amounts for Dr. Zeskind, Dr. Hall and Mr. Bookman in 2024 were 50%, 30% and 40%, respectively.

In February 2025, the compensation committee evaluated the named executive officers’ performance against the Company’s performance and approved the amounts earned by our named executive officers under the Company’s annual bonus program for 2024 and included above in the “ Bonus ” column of the 2024 Summary Compensation Table